Drugs / AST-OPC1
AST-OPC1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02302157 | Mar 2015 → Dec 2018 | spinal cord injury | Lineage Cell Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-06-13 | Aivita Biomedical, Inc. | Results AIVITA Comments on Positive Findings from Asterias’ SCiStar Trial for Spinal Cord Injury aivitabiomedical.com ↗
AIVITA Biomedical offered its congratulations today following the announcement of positive 9-month efficacy and safety data from Asterias Biotherapeutics’ SCiStar Phase 1/2a clinical study for patients with complete cervical spinal cord injury (SCI). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-06-13 | Aivita Biomedical, Inc. | AIVITA Comments on Positive Findings from Asterias’ SCiStar Trial for Spinal Cord Injury aivitabiomedical.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AST-OPC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02302157 ↗ |
| Known as | GRNOPC1 | “oligodendrocyte progenitor cells (LCTOPC1; previously known as GRNOPC1 and AST-OPC1)” PMID 35901693 ↗ Jul 2022 |
| Known as | LCTOPC1 | “oligodendrocyte progenitor cells (LCTOPC1; previously known as GRNOPC1 and AST-OPC1)” PMID 35901693 ↗ Jul 2022 |
| Modality | Cell therapy | “oligodendrocyte progenitor cells (LCTOPC1; previously known as GRNOPC1 and AST-OPC1)” PMID 35901693 ↗ Jul 2022 |
| Route | Other | “delivered via intraparenchymal injection into the spinal cord” PMID 35901693 ↗ Jul 2022 |